Five things for pharma marketers to know: Tuesday, May 23, 2017

Share this content:

1. Disease awareness ads, which the FDA does not regulate, can raise prescription drug sales and lead to overdiagnosis due to requests from patients who see the ads, a new study found. (Modern Healthcare)

2. Severe asthma patients treated with AstraZeneca's experimental drug benralizumab in a Phase-III trial were able to cut the use of steroids and reported a reduction in asthma attacks, compared to those taking a placebo. (Reuters)

3. The FDA approved a rheumatoid arthritis drug, Kevzara, developed by Regeneron Pharmaceuticals and Sanofi. The drugmakers said the list price of the therapy, at $39,000 per year, is 30% lower than that of its competitors. (PharmaTimes)

4. The Competition and Markets Authority, the U.K.'s competition regulator, criticized Merck for restricting biosimilar competition for Remicade, which treats rheumatoid arthritis, Crohn's disease and ulcerative colitis, with the use of discounts awarded to customers who did not switch to biosimilars. (Reuters)

5. ICYMI: Instagram and Snapchat were ranked as the top two social media platforms detrimental to the mental health of young people between the ages of 14 and 24 years old in the U.K, while YouTube had the most positive impact. (Business Insider)

Share this content:
Scroll down to see the next article